{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:46:34Z","timestamp":1792118794898,"version":"4.4.0"},"reference-count":92,"publisher":"Microbiology Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:p>Infection with human papillomaviruses (HPVs) is very common and associated with benign and malignant epithelial proliferations of skin and internal squamous mucosae. A subset of the mucosal HPVs are oncogenic and associated with 5\u200a% of all cancers in men and women. There are two licensed prophylactic vaccines, both target HPV 16 and 18, the two most pathogenic, oncogenic types and one, additionally, targets HPV 6 and 11 the cause of genital warts. The approach of deliberate immunization with oncogenic HPV E6 and\/or E7 proteins and the generation of antigen-specific cytotoxic T-cells as an immunotherapy for HPV-associated cancer and their high-grade pre-cancers has been tested with a wide array of potential vaccine delivery systems in Phase I\/II trials with varying success. Understanding local viral and tumour immune evasion strategies is a prerequisite for the rational design of therapeutic vaccines for HPV-associated infection and disease, progress in this is discussed. There are no antiviral drugs for the treatment of HPV infection and disease. Current therapies are not targeted antiviral therapies, but either attempt physical removal of the lesion or induce inflammation and a bystander immune response. There has been recent progress in the identification and characterization of molecular targets for small molecule antagonists of the HPV proteins E1, E2 and E6 or their interactions with their cellular targets. Lead compounds that could disrupt E1\u2013E2 protein\u2013protein interactions have been discovered as have inhibitors of E6\u2013E6-AP-binding interactions. Some of these compounds showed nanomolar affinities and high specificities and demonstrate the feasibility of this approach for HPV infections. These studies are, however, at an early phase and it is unlikely that any specific anti-HPV chemotherapeutic will be in the clinic within the next 10\u201320 years.<\/jats:p>","DOI":"10.1099\/vir.0.039677-0","type":"journal-article","created":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T01:33:10Z","timestamp":1328751190000},"page":"681-691","source":"Crossref","is-referenced-by-count":81,"title":["Genital human papillomavirus infections: current and prospective therapies"],"prefix":"10.1099","volume":"93","author":[{"given":"Margaret A.","family":"Stanley","sequence":"first","affiliation":[{"name":"Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.11.002"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20013"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2000.1742"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0328"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr015"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1786"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1021\/bi0019592"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.2174\/187152006778226468"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.002"},{"key":"r10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.02.020"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.13.5799"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065497"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605611"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e3282f75ea1"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3493"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1421"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.12.006"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1021\/jm034206x"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.7.4447"},{"key":"r23","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0b013e32833d466c","article-title":"A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod","volume":"24","author":"Fox","year":"2010","journal-title":"AIDS"},{"key":"r24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/135965350701200417","article-title":"Recent advances in the search for antiviral agents against human papillomaviruses","volume":"12","author":"Fradet-Turcotte","year":"2007","journal-title":"Antivir Ther"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02468-08"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2007.01.036"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1352.016"},{"key":"r28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/135965350601100607","article-title":"Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro","volume":"11","author":"Hampson","year":"2006","journal-title":"Antivir Ther"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biophys.31.100901.142129"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgl172"},{"key":"r31","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1128\/JVI.73.5.4404-4412.1999","article-title":"Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites","volume":"73","author":"Ilves","year":"1999","journal-title":"J Virol"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810377186"},{"key":"r33","first-page":"583","article-title":"Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis","volume":"32","author":"Jablonska","year":"1972","journal-title":"Cancer Res"},{"key":"r34","first-page":"393","article-title":"Vulval intraepithelial neoplasia: current perspectives","volume":"22","author":"Jones","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3636"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1039\/b923046g"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908502106"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0031"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00177-0"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.10.020"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.015"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1021\/bi049552a"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.19.8895"},{"key":"r45","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1128\/JVI.72.9.7407-7419.1998","article-title":"A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit","volume":"72","author":"Masterson","year":"1998","journal-title":"J Virol"},{"key":"r46","doi-asserted-by":"publisher","DOI":"10.1258\/095646204774195173"},{"key":"r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.10.002"},{"key":"r48","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1128\/JVI.71.10.7381-7386.1997","article-title":"Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA","volume":"71","author":"Meyers","year":"1997","journal-title":"J Virol"},{"key":"r49","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2886"},{"key":"r50","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1099\/0022-1317-83-9-2299","article-title":"COPV DNA absence following prophylactic L1 PMID vaccination","volume":"83","author":"Moore","year":"2002","journal-title":"J Gen Virol"},{"key":"r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.018"},{"key":"r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.01.024"},{"key":"r53","first-page":"279","article-title":"[Plurality of human papillomaviruses (author\u2019s transl)]","volume":"105","author":"Orth","year":"1978","journal-title":"Ann Dermatol Venereol"},{"key":"r54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.120"},{"key":"r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.111"},{"key":"r57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600078103"},{"key":"r58","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-199509000-00022"},{"key":"r59","doi-asserted-by":"publisher","DOI":"10.1038\/nm1598"},{"key":"r60","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr061"},{"key":"r61","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.23.7044"},{"key":"r62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.07400.x"},{"key":"r63","doi-asserted-by":"publisher","DOI":"10.2741\/3123"},{"key":"r64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.7.2865"},{"key":"r65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3141"},{"key":"r66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914818107"},{"key":"r67","doi-asserted-by":"publisher","DOI":"10.1053\/beog.2001.0221"},{"key":"r68","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01151.x"},{"key":"r69","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.09.002"},{"key":"r70","doi-asserted-by":"publisher","DOI":"10.2165\/11532810-000000000-00000"},{"key":"r71","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.11.6439"},{"key":"r72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09375.x"},{"key":"r73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.12.340"},{"key":"r74","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1128\/JVI.73.7.5282-5293.1999","article-title":"Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin","volume":"73","author":"Titolo","year":"1999","journal-title":"J Virol"},{"key":"r75","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.16.7349-7361.2000"},{"key":"r76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5178-5191.2003"},{"key":"r77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70227-X"},{"key":"r78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002756"},{"key":"r79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704672104"},{"key":"r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.06.042"},{"key":"r81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-4632.2009.04375.x","article-title":"Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options","volume":"49","author":"Viera","year":"2010","journal-title":"Int J Dermatol"},{"key":"r82","doi-asserted-by":"publisher","DOI":"10.1136\/sti.76.3.162"},{"key":"r83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006500107"},{"key":"r84","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101932200"},{"key":"r85","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.4834-4842.2005"},{"key":"r86","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_92"},{"key":"r87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24804"},{"key":"r88","doi-asserted-by":"publisher","DOI":"10.1038\/353628a0"},{"key":"r89","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/19.4.611"},{"key":"r90","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00510-9"},{"key":"r91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2787"},{"key":"r92","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(81)90067-6"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.039677-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:20:38Z","timestamp":1686745238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.039677-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.039677-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}